IDEXX Laboratories, Inc. $(IDXX)$, a leader in pet healthcare innovation, has announced its second-quarter 2025 results, reporting revenues of $1.109 billion. The company experienced a significant increase in its operating margin, which stood at 33.6% for the quarter, reflecting an improvement of 730 basis points compared to the prior year period. The Companion Animal Group $(CAG)$ segment led revenue growth, with CAG Diagnostics recurring revenue increasing by 9% as reported and 7% organically. International regions saw reported gains of 15% and organic gains of 11%, while the U.S. experienced 6% growth in both reported and organic terms. This growth was driven by the successful commercial execution, net customer gains, and increased diagnostic utilization, supported by recent innovations like the IDEXX InVue Dx™ and IDEXX Cancer Dx™. For the full-year 2025 outlook, IDEXX Laboratories has updated its revenue growth guidance to a range of $4.205 billion to $4.280 billion, reflecting reported growth of 7.7% to 9.7%. The company has also increased its outlook for organic revenue growth to 7% to 9%, noting solid performance in CAG Diagnostics recurring revenue and expectations for higher IDEXX InVue Dx instrument placements and revenues. The weakening of the U.S. dollar has also contributed positively to these projections.